The Europe preimplantation genetic testing (PGT) market size is valued at USD 148.40 million in 2021 and is expected to reach USD 252.78 million by 2026, to grow at a CAGR of 11.24% over the forecast period 2021 to 2026.
The increased uptake of IVF following pregnancy-related complications is expected to drive demand for preimplantation genetic testing services. Women undergoing IVF should undergo cycles of PGT to prevent the transmission of chromosomal abnormalities from the offspring, which in turn increases growth.
The main factor attributed to the growth of the market is increased parental awareness of diagnostic advancements with high volume of neonatal deaths due to complications in childbirth. In recent years, the increasing prevalence of congenital genetic diseases such as Edwards syndrome and common pediatric respiratory disorders such as pneumonia and asthma has been observed
According to estimates released by the United Nations Children's Fund (UNICEF) in November 2018, there are approximately 3.1 million pediatric pneumonia deaths worldwide each year. These abnormalities occur almost exclusively in couples with inherited disorders, which have been found to occur mainly in industrialized countries. Therefore, increased demand for earlier diagnosis and increased government efforts to control the burden of healthcare are likely to stimulate the market for preimplantation genetic testing.
In 2019 3,450 cycles of PGT were performed in the UK, resulting in the birth of 1,174 babies with PGT. This gives an egg collection success rate for PGT of 33% for the UK .These data shows the importance of preimplantation genetic testing and development of healthy baby.
High costs of the testing kits have been a major source of restraint for the market growth rate and is expected to continue the same for upcoming years. Medical Advancements in the understanding for genetics and IVF medicine industry in ELISA, HLA and stem cell technology will give rise to better opportunities for market growth. Awareness about these preimplantation genetic testing kits and IVF treatment availability in some regions of European countries has challenged market growth rate.
This research report on the Europe Preimplantation Genetic Testing Market has been segmented and sub-segmented into the following categories:
By Procedure Type:
By Products & Services:
By End User:
The United Kingdom is expected to dominate the market for Europe preimplantation genetic testing. The prevalence is due to an increasing volume of cases of chromosomal abnormalities leading to various genetic disorders. Aneuploidy is the most common cause of Down syndrome in newborns in the UK, which accounts for the largest number for genetic disorders across the European regions. According to the World Health Organization report released in 2018, Down syndrome remains the most common chromosomal disease affecting 4,500 babies born each year. This, in turn, has generated a strong demand for early diagnostics to identify genetic defects in embryos that fuel the market in the region. New product launches by medical companies and increased improvements in healthcare infrastructure in the Europe generates more revenue. The increase in public awareness initiatives and the growing preference of couples for these tests during IVF and other artificial insemination procedures are further driving the growth of the preimplantation genetic testing market in the region.
France accounts to second largest share in market due the developed infrastructure, the increase in investments by government agencies and the presence of major companies in this region, collectively promote the growth of this industry in this region.
Key players operating in the Europe Preimplantation Genetic Testing Market profiled in this report are Illumina, Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc., and SciGene Corporation.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Procedure Type
5.1.2 Preimplantation Genetic Screening
5.1.3 Preimplantation Genetic Screening
5.1.4 Y-o-Y Growth Analysis, By Procedure Type
5.1.5 Market Attractiveness Analysis, By Procedure Type
5.1.6 Market Share Analysis, By Procedure Type
5.2.2 Next-Generation Sequencing
5.2.3 Polymerase Chain Reaction
5.2.4 Validation Biomarkers
5.2.5 Fluorescence in Situ Hybridization
5.2.6 Comparative Genomic Hybridization
5.2.7 Single-Nucleotide Polymorphism
5.2.8 Y-o-Y Growth Analysis, By Technology
5.2.9 Market Attractiveness Analysis, By Technology
5.2.10 Market Share Analysis, By Technology
5.3 Product and Service
5.3.2 Reagents and Consumables
5.3.4 Software and Services
5.3.5 Y-o-Y Growth Analysis, By Product and Service
5.3.6 Market Attractiveness Analysis, By Product and Service
5.3.7 Market Share Analysis, By Product and Service
5.4.3 Structural Chromosomal Abnormalities
5.4.4 Single Gene Disorders
5.4.5 X-Linked Disorders
5.4.6 HLA Typing
5.4.7 Gender Identification
5.4.8 Y-o-Y Growth Analysis, By Application
5.4.9 Market Attractiveness Analysis, By Application
5.4.10 Market Share Analysis, By Application
5.5 End users
5.5.2 Maternity Centers & Fertility Clinics
5.5.3 Hospitals, Diagnostic Labs, and Service Providers
5.5.4 Research Laboratories & Academic Institutes
5.5.5 Y-o-Y Growth Analysis, By End users
5.5.6 Market Attractiveness Analysis, By End users
5.5.7 Market Share Analysis, By End users
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Procedure type
188.8.131.52 By Technology
184.108.40.206 By Product and Service
220.127.116.11 By Application
18.104.22.168 By End user
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Procedure type
188.8.131.52 By Technology
184.108.40.206 By Product and Service
220.127.116.11 By Application
18.104.22.168 By End user
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Procedure type
188.8.131.52 By Technology
184.108.40.206 By Product and Service
220.127.116.11 By Application
18.104.22.168 By End user
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Illumina, Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific Inc.
8.3 Agilent Technologies, Inc.
8.4 Perkinelmer, Inc.
8.5 Coopersurgical, Inc.
8.6 ABBott Laboratories
8.7 Natera, Inc.
8.8 Rubicon Genomics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures